Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 67 clinical trials
None
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.

stem cell transplantation
remission
renal function
mental disorders
refractory multiple myeloma
  • 0 views
  • 14 Mar, 2021
  • 1 location
None
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patient.

neutrophil count
platelet count
bone marrow procedure
refractory multiple myeloma
ejection fraction
  • 0 views
  • 24 Jan, 2021
  • 1 location
None
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

This is a single-center, non-randomized study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patients.

bcma
monoclonal antibodies
bone marrow procedure
refractory multiple myeloma
monoclonal protein
  • 0 views
  • 24 Jan, 2021
  • 1 location
None
Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

This study is aimed to evaluate the safety, feasibility and efficacy of BCMA CAR-T in the treatment of relapsed or refractory multiple myeloma

ejection fraction
fludarabine
immunohistochemistry
refractory multiple myeloma
bcma
  • 0 views
  • 25 Jan, 2021
  • 2 locations
None
Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma

(multiple myeloma). BCMA (B cell maturation antigen) is a promising target for malignant plasma cells. Therefore, we designed a clinical trial using anti-BCMA CAR-T cell therapy for patients with relapsed

  • 0 views
  • 26 Jan, 2021
  • 1 location
None
BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

This is a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA

measurable disease
daratumumab
refractory multiple myeloma
lenalidomide
bcma
  • 0 views
  • 25 Nov, 2021
  • 2 locations
None
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma

This is a single arm study to evaluate the efficacy and safety of BCMA-targeted prime CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.

cell transplantation
refractory multiple myeloma
chemotherapy regimen
  • 0 views
  • 08 Aug, 2021
  • 1 location
None
Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma

Evaluation the safety,tolerability, preliminary efficacy,and PK/PD of CD19-BCMA CAR-T cells for the treatment of multiple myeloma

  • 0 views
  • 31 Jan, 2021
  • 1 location
None
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma

The goal of this clinical trial is to study the feasibility and efficacy of anti-B-Cell Maturation Antigen (BCMA) expressing T cells in treating patients with multiple myeloma.

cell transplantation
refractory multiple myeloma
fludarabine
  • 0 views
  • 06 Sep, 2021
  • 1 location
None
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma

progressive systemic sclerosis
scleroderma
  • 0 views
  • 28 Oct, 2021
  • 1 location